Genetic Polymorphisms and Toxicities of First-Line Antituberculosis Drugs: Systematic Review of the Literature
Open Access
- 1 January 2022
- journal article
- review article
- Published by Scientific Research Publishing, Inc. in Journal of Tuberculosis Research
- Vol. 10 (03), 124-145
- https://doi.org/10.4236/jtr.2022.103010
Abstract
Introduction: Polymorphisms are the main genetic factors associated with toxicities of antituberculosis drugs. This literature review summarizes the polymorphisms of the genes that code for the enzymes of the metabolism of antituberculosis drugs and their transmembrane transporters. Some mechanisms of drug-associated toxicities and strategies for their management have also been described in this review. Methods: The bibliographic searches were exclusively carried out in PubMed, over a period of ten years (2010-2020). The search terms were the words “toxicity + antituberculosis drug + one or two word(s) among the following: polymorphism, genetics, mutation, SNP, HLA or haplotype”. Publications in English or French, relating to the various toxicities associated with first-line anti-tuberculosis drugs (Rifampicin, Isoniazid, Ethambutol and Pyrazinamide) administered to patients with pulmonary tuberculosis, extrapulmonary tuberculosis or co-infected with TB/HIV were included in this review. Duplicates, in vitro, in silico or drug-induced toxicity studies other than antituberculosis drugs and genetic mutations of Mycobacteria strains were not included. Results: The studies selected and included were case reports, cohort studies, original research, systematic reviews and meta-analyses on human subjects of different ethnic origins. Hepatotoxicity is the most common toxicity associated with NAT2, CYP2E1, GSTM1 and GSTT1 polymorphisms in patients on antituberculosis drugs. Other forms of toxicity, less frequent, occurring in certain patients under concomitant treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), antiretrovirals (ARVs), antibiotics or antiepileptics have also been identified. Conclusion: The genetic polymorphisms associated with the toxicities of antituberculosis drugs concern both the main enzymes of the metabolic pathways (NAT2, CYP2E1, GST) and the transmembrane transporters (SLCO1B1 and ABCB1). Other genetic polymorphisms (TXNRD1, SOD2, TYMP) have been suspected but their mechanisms are not yet well understood.Keywords
This publication has 56 references indexed in Scilit:
- Association of GST Genetic Polymorphisms with the Susceptibility to Hepatocellular Carcinoma (HCC) in Chinese Population Evaluated by an Updated Systematic Meta-AnalysisPLOS ONE, 2013
- Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapyClinica Chimica Acta; International Journal of Clinical Chemistry, 2013
- The roles ofGSTM1andGSTT1null genotypes and other predictors in anti-tuberculosis drug-induced liver injuryJournal of Clinical Pharmacy & Therapeutics, 2012
- CYP2E1,GSTM1andGSTT1genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control studyJournal of Clinical Pharmacy & Therapeutics, 2012
- Genetic association studies in drug-induced liver injuryDrug Metabolism Reviews, 2012
- Polymorphisms in drug transporter genes (ABCB1, SLCO1B1 and ABCC2) and hepatitis induced by antituberculosis drugsTuberculosis, 2012
- Involvement of Different Human Glutathione Transferase Isoforms in the Glutathione Conjugation of Reactive Metabolites of TroglitazoneDrug Metabolism and Disposition, 2011
- Glutathione S-transferase genetic polymorphisms (GSTM1, GSTT1 and GSTO2) in three Iranian populationsMolecular Biology Reports, 2009
- IsoniazidTuberculosis, 2008
- Drug hepatotoxicity.British Journal of Clinical Pharmacology, 1983